Search Results

Site Search

1939: Lou Gehrig Comes to Mayo Clinic #ThrowbackThursday - Insights

They called him the "Iron Horse" and the "Pride of the Yankees." But when baseball great Lou Gehrig came to Mayo Clinic in June 1939, his name became associated with an illness called amyotrophic lateral sclerosis (ALS). Today, ALS is known...

Insights - Insights

Skip to Content MayoACCESS MayoLINK...

New gene panel enhances brain tumor profiles - Insights

Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.

Comprehensive panel boosts GIST diagnosis sensitivity - Insights

Rondell Graham, M.B.B.S., describes Mayo Clinic Laboratories' new assay for gastrointestinal stromal tumors, or GIST. The panel covers multiple mutations, to better inform diagnosis and treatment options.

Carrier Screening [Test in Focus] - Insights

Michelle Kluge, M.S., CGC, explains how Mayo Clinic Laboratories’ CYPZ assay provides accurate testing for congenital adrenal hyperplasia. Using an in-depth methodology that incorporates Sanger sequencing, MCL can provide clear answers for...

ACHE 2017 Congress on Healthcare Leadership Live Blog - Insights

Andy Cousin, FACHE, Director of Product Management and Marketing for Mayo Medical Laboratories, is attending this year's ACHE Congress on Health Care Leadership conference in Chicago. He will be sharing his thoughts and photos from the...

Graduation Is upon Us - Insights

Elizabeth Gamache, a student in Mayo Clinic’s Medical Laboratory Science class of 2018, discusses the 2018's class impending graduation and what they have to look forward to afterward.

Week in Review: May 27 - Insights

Today's highlights include: Long COVID affects more older adults, US has a new dominant COVID-19 strain, and Gianrico Farrugia explains how we can transform healthcare by moving from pipeline to platform.

Neurofilament light chain test helps in diagnosis, treatment, and prognosis of ALS and MS - Insights

By using a test that measures neurofilament light chain (Nfl) proteins in blood, clinicians can better diagnose devastating diseases like ALS and MS, help predict disease progression, and better assess efficacy of existing drugs and trial...

MCL DrMcKeon PAVAL letter MC2775682

MCL DrMcKeon PAVAL letter Dear Colleague partnering Clinic Laboratories autoimmune neurology testing effort offer